Active Compounds From Inga edulis Martius Seeds Against Multiple Myeloma

Abstract

Multiple myeloma is an incurable hematological cancer with an average survival time of only 5 to 10 years due to the high rate of relapse and resistance. Although the introduction of novel classes of drugs has improved the standard of care, new strategies are urgently needed. Plants are primary sources of bioactive natural compounds for cancer treatment. This study aimed at evaluating the in vitro inhibitory activity of the Inga edulis seed extract against multiple myeloma cells, as well as the compounds isolated from this extract. The ethanolic extract of the seeds of I. edulis inhibited 85% of RPMI 8226 cell proliferation at 20 µg/mL. Then, the extract was subjected to a bioassay-guided fractionation to afford 3 saponins known as concinnoside D (1), julibroside A1 (2), and julibroside A3 (3). The isolated saponins exhibited antiproliferative activity with IC50 values in the low µM range for compounds 2 and 3. Compound 1 was considered inactive (IC50 > 20 µM). Therefore, the seeds of I. edulis could be considered as a source of active compounds against multiple myeloma.